Prediction of pathological complete response after neoadjuvant chemotherapy for HER2-negative breast cancer patients with routine immunohistochemical markers
- Published on 01/30/2025
- Reading time: 5 min.
Häberle Lothar 1,2, Erber Ramona 3, Gass Paul 1, Hein Alexander 1, Niklos Melitta 1, Volz Bernhard 1,4, Hack Carolin C. 1, Schulz-Wendtland Rüdiger 5, Huebner Hanna 1, Goossens Chloë 1, Christgen Matthias 6, Dörk Thilo 7, Park-Simon Tjoung-Won 8, Schneeweiss Andreas 9, Untch Michael 10, Nekljudova Valentina 11, Loibl Sibylle 11, Hartmann Arndt 3, Beckmann Matthias W. 1, Fasching Peter A. 1
1 https://ror.org/00f7hpc57 Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen–Nuremberg Erlangen Germany
2 https://ror.org/0030f2a11 Biostatistics Unit, Department of Gynecology and Obstetrics Erlangen University Hospital Erlangen Germany
3 https://ror.org/0030f2a11 Institute of Pathology, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen–Nuremberg Erlangen Germany
4 https://ror.org/0167rnj42 Ansbach University of Applied Sciences Ansbach Germany
5 https://ror.org/00f7hpc57 Institute of Diagnostic Radiology, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen–Nuremberg Erlangen Germany
6 https://ror.org/00f2yqf98 Institute of Pathology, Hannover Medical School Hannover Germany
7 https://ror.org/00f2yqf98 Gynecology Research Unit Hannover Medical School Hannover Germany
8 https://ror.org/00f2yqf98 Department of Gynecology and Obstetrics, Hannover Medical School Hannover Germany
9 https://ror.org/04cdgtt98 National Center for Tumor Diseases University Hospital and German Cancer Research Center Heidelberg Germany
10 https://ror.org/05hgh1g19 Department of Gynecology and Obstetrics Helios Clinic Berlin-Buch Berlin Germany
11 https://ror.org/03c8hnh70 German Breast Group Neu-Isenburg Germany
Abstract
Background Pathological complete response (pCR) is an established surrogate marker for prognosis in patients with breast cancer (BC) after neoadjuvant chemotherapy. Individualized pCR prediction based on clinical information available at biopsy, particularly immunohistochemical (IHC) markers, may help identify patients who could benefit from preoperative chemotherapy.
Methods Data from patients with HER2-negative BC who underwent neoadjuvant chemotherapy...
To continue reading this article in Full-Text...
Peer-Reviewed Journals A-Z
Search | Advanced search
Get the latest news in Oncology
Receive our newsletter to stay up to date with the latest news in Oncology